Over at Genetic Future, Daniel MacArthur blogs about Complete Genomics and its deal to sequence five genomes for the Broad Institute -- one genome of a well-studied test case, and four from "tumor and matched-pair normals" to study glioblastoma and melanoma. MacArthur spoke with Complete's Geoff Nilsen about accuracy issues. While data estimates are still rough, "based on preliminary quality control data, Nilsen very cautiously estimated that they had somewhere in the vicinity of 80,000-100,000 false positive calls, and perhaps around 1,000 false negatives, for single nucleotide polymorphisms in their pilot genome sequence," MacArthur writes.
The Complete Five
Mar 04, 2009